ADHD Medication and Ibogaine: The CYP2D6 Problem Nobody Screens For

There is a sentence that shows up on intake forms with some regularity, and it is one of the more dangerous sentences in this field:

"No, nothing — well, just my Adderall, but that's prescribed."

ADHD medication occupies a strange blind spot. It is not thought of as a drug in the way the intake form seems to mean. It has been taken daily for years. It came from a physician. It feels like part of the furniture rather than part of the medical history.

It is also, depending on which medication it is, capable of interacting with ibogaine along three separate axes at once — cardiac, metabolic, and serotonergic. And ADHD is substantially more common in people seeking treatment for substance use disorder than in the general population, which means this is not an edge case. It is a routine case that is routinely under-screened.

This guide walks through what each class of ADHD medication does in the context of ibogaine, and why one of them — a medication that is not even a stimulant — is arguably the most important item on this entire list.

This is educational information, not medical advice. Do not start, stop, or change any prescribed medication based on an article. Stimulant and non-stimulant discontinuation must be planned with the prescribing physician.

The Foundation: Ibogaine Runs Through CYP2D6

Everything below rests on one piece of pharmacology, so it is worth stating plainly.

Ibogaine is metabolized in the liver primarily by the enzyme CYP2D6, which converts it into its major active metabolite, noribogaine. Noribogaine has a substantially longer half-life than ibogaine itself, which is why the physiological window after a session extends well past the point where the subjective experience has ended.

CYP2D6 is one of the most genetically variable enzymes in human pharmacology. People are commonly grouped as poor, intermediate, normal, or ultra-rapid metabolizers, and the distribution differs meaningfully across populations. A poor metabolizer clears ibogaine slowly. Slower clearance means higher peak concentration and a longer period of exposure — and because ibogaine's principal acute danger is its effect on cardiac repolarization (QT prolongation), a longer exposure window means a longer window in which a dangerous arrhythmia can occur.

This is the reason serious programs build their protocol around the cardiac screen. If you have not read the fundamentals, start with ibogaine safety and the ibogaine treatment process before going further here.

Hold that in mind, because the most important interaction in this article is not a stimulant at all.

Bupropion: The One That Changes Your Metabolism

Bupropion — sold as Wellbutrin and, for smoking cessation, Zyban — is widely prescribed for ADHD off-label, particularly in patients with a substance use history where prescribers want to avoid a controlled stimulant. It also shows up as an antidepressant, which means many people carrying it do not mentally file it under "ADHD medication" at all.

Bupropion is a strong CYP2D6 inhibitor.

Read that against the previous section. Ibogaine is cleared by CYP2D6. A strong inhibitor of CYP2D6 can effectively convert a genetically normal metabolizer into a functional poor metabolizer — producing, pharmacologically, the exact high-exposure state that makes ibogaine most dangerous, in a patient whose genetics would otherwise have placed them in a lower-risk group.

This has three consequences that matter operationally:

1. Genetic testing alone is not sufficient. A CYP2D6 genotype result describes capacity, not current activity. A patient can genotype as a normal metabolizer and be phenotypically poor because of what they are taking. The phrase for this is phenoconversion, and it is invisible to any screen that only looks at genes.
2. Weight-based dosing assumptions break. Dosing protocols that assume typical clearance are built on an assumption bupropion invalidates.
3. The washout is long. Bupropion and its active metabolites have extended half-lives, and CYP2D6 inhibition does not stop the moment the last dose is swallowed. Any taper must be planned well in advance with the prescriber — not days before travel.

Bupropion also independently lowers the seizure threshold, which is its best-known safety property and one that compounds a separate concern discussed below.

If you take bupropion for any reason — mood, ADHD, smoking cessation — it belongs at the top of the disclosure list. Run every medication you take through a medication interaction checker and bring the results to the screening conversation.

Atomoxetine: A Substrate Competing for the Same Enzyme

Atomoxetine (Strattera) is the other non-stimulant that matters, and for a different reason. Atomoxetine is itself a CYP2D6 substrate — its own labeling carries reduced dosing guidance for known poor metabolizers, because poor metabolizers reach far higher plasma concentrations at the same dose.

Two implications:

• Two CYP2D6 substrates present at once compete for a finite amount of enzyme, and neither behaves the way its label predicts.
• More usefully: an existing atomoxetine prescription is a clue. If a patient has ever had a dose reduction, unusual side effects at a standard dose, or a documented poor-metabolizer status related to atomoxetine, that is a fragment of CYP2D6 phenotype data sitting in their existing medical record. It is worth asking for.

Atomoxetine is also a norepinephrine reuptake inhibitor, and carries labeled cardiovascular cautions — increases in heart rate and blood pressure, and warnings around structural cardiac abnormalities. That merges directly into the cardiac picture.

The Stimulants: Opposing Cardiac Effects, and a Serotonergic Question

Amphetamine class: Adderall, Vyvanse (lisdexamfetamine), Dexedrine. Methylphenidate class: Ritalin, Concerta, Focalin.

These are sympathomimetics. They raise heart rate and blood pressure. Ibogaine, by contrast, characteristically produces bradycardia — a slowed heart rate — alongside QT prolongation.

It is tempting to read that as cancellation. It is not. Two drugs pushing a system in opposite directions do not produce a stable middle; they produce a system under competing loads, with a baseline that has moved and is no longer the baseline the monitoring protocol was calibrated against. Specific concerns:

• Masked bradycardia. Residual stimulant can hold heart rate in an apparently acceptable range, concealing the degree of ibogaine-induced bradycardia underneath. The number on the monitor looks fine. The underlying physiology is not.
• Rebound on withdrawal. Stimulant discontinuation produces its own cardiovascular and psychological rebound — fatigue, hypersomnia, depressed mood, sometimes marked. If that taper is scheduled close to treatment, the crash lands during the pre-treatment window, and the resulting low mood is easily misattributed.
• Electrolyte and hydration effects. Stimulants suppress appetite and can reduce fluid and food intake. Potassium and magnesium status is central to QT risk. A patient who has been eating poorly for weeks arrives with a worse electrolyte picture than their chart suggests.
• Serotonergic overlap. Amphetamines act on monoamine release including serotonin, and ibogaine and noribogaine have serotonergic activity of their own. Serotonin toxicity is a recognized concern in ibogaine drug-interaction discussions — most prominently with SSRIs and other serotonergic agents, but the principle extends.

Methylphenidate has a somewhat different pharmacological profile from the amphetamines — primarily reuptake inhibition rather than release — and less CYP2D6 involvement. Different profile, not an absence of one. The cardiac and rebound considerations remain.

Where stimulant use is not prescribed but recreational or dependent, that is a materially different clinical situation, addressed in ibogaine for alcohol and stimulant dependence.

Alpha-2 Agonists: Bradycardia Stacked on Bradycardia

Guanfacine (Intuniv) and clonidine (Kapvay) are non-stimulant ADHD medications, used frequently in younger patients and increasingly in adults, and often prescribed alongside a stimulant rather than instead of one.

Both are alpha-2 adrenergic agonists. Both lower heart rate and blood pressure. Both can produce rebound hypertension on abrupt discontinuation — clonidine notably so.

The interaction shape is straightforward and unforgiving: ibogaine causes bradycardia; alpha-2 agonists cause bradycardia; the effects stack in the same direction. This is the cleanest additive cardiac risk on the list, and because these are not controlled substances and are often thought of as mild, they are among the most likely to be omitted from a disclosure. They are also frequently prescribed for sleep or anxiety rather than ADHD, further obscuring the connection.

Abrupt discontinuation is its own hazard. This is a taper that requires a prescriber, not a decision made the week before travel.

Why the Disclosure Fails

The pattern is consistent enough to name. ADHD medications get omitted because:

• "It's prescribed" reads as categorically different from a drug, so the question does not seem to apply.
• Non-stimulants are not thought of as ADHD medication. Guanfacine prescribed for sleep, bupropion prescribed for mood, atomoxetine started years ago — patients name the indication, not the class.
• PRN and weekend-off dosing. Many adults skip stimulants on weekends or take them only on demand. Asked "do you take a daily medication," they accurately answer no.
• Fear of being turned away. Patients who suspect a disclosure will disqualify them sometimes edit. This is the most dangerous of the four, and the only defense is a screening process that is clearly framed as protective rather than gatekeeping.

The countermeasure is not a better-worded question. It is a medication reconciliation — a pharmacy printout or an actual list of everything taken in the last ninety days regardless of indication, frequency, or perceived relevance, including over-the-counter products and supplements.

What an Adequate Screen Looks Like

If you take any medication in this article, an appropriate screening process should include:

1. A full ECG with a calculated QTc, plus a documented baseline heart rate and blood pressure taken after any stimulant taper, not before. A baseline recorded while a stimulant is on board is not a baseline.
2. Serum potassium and magnesium, with correction before dosing. Non-negotiable where appetite has been suppressed.
3. Explicit CYP2D6 consideration — genotype where available, and just as importantly a review of every CYP2D6 inhibitor currently on board. Bupropion, paroxetine, fluoxetine, duloxetine, and quinidine are the classic ones; Cymbalta's interaction with ibogaine covers one of them in detail.
4. A taper plan authored by the prescribing physician, with washout intervals appropriate to each drug's half-life and, for CYP2D6 inhibitors, to the duration of enzyme inhibition rather than just drug clearance.
5. A rebound plan. Stimulant withdrawal has a predictable trajectory. It should be expected and managed, not discovered.
6. Continuous cardiac monitoring during the active window, which is the standard the cardiac risk demands regardless of ADHD medication.

You can work through a preliminary version of this yourself using the ibogaine pre-screening tool, then bring it to a real clinical conversation. When evaluating programs, ask directly how they handle CYP2D6 inhibitors — choosing a clinic covers the broader set of questions worth asking, and a program that cannot answer this one has told you something important.

The Short Version

• Ibogaine is cleared by CYP2D6, and slower clearance means a longer QT risk window.
• Bupropion is a strong CYP2D6 inhibitor and can turn a normal metabolizer into a functional poor one — the single highest-leverage item here, and it is not a stimulant.
• Atomoxetine competes for the same enzyme, and a patient's history with it may contain usable phenotype information.
• Stimulants raise heart rate against ibogaine's bradycardia, can mask it on the monitor, and degrade electrolyte status through appetite suppression.
• Guanfacine and clonidine stack bradycardia in the same direction as ibogaine — the most-omitted and most directly additive risk.
• Every one of these lands back on the same place: the cardiac screen.

Disclose everything. The screening exists to keep you alive, not to keep you out.

For background on the substance itself, see what is ibogaine, and for common questions the ibogaine FAQ.

---

This article is educational information and is not medical advice. It does not establish a physician-patient relationship. Ibogaine is a Schedule I controlled substance in the United States and carries documented cardiac risks including QT prolongation and cases of sudden cardiac death. Never start, stop, or adjust a prescribed medication without your prescribing physician. Ibogaine Treatment Guide is an independent informational resource and is not a treatment provider. If you are in crisis, call or text 988 (Suicide & Crisis Lifeline) in the US.